S-Ruxolitinib (INCB018424)
- CAS NO.:941685-37-6
- Empirical Formula: C17H18N6
- Molecular Weight: 306.36
- MDL number: MFCD13184797
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-08-06 16:32:36
What is S-Ruxolitinib (INCB018424)?
The Uses of S-Ruxolitinib (INCB018424)
(3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile is a newly developed JAK2 inhibitor therapy aimed to improve MPN-associated splenomegaly and systemic symptoms.
The Uses of S-Ruxolitinib (INCB018424)
(3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile is a newly developed JAK2 inhibitor therapy aimed to improve MPN-associated splenomegaly and systemic symptoms. The opposite enantiomer of Ruxolitinib (R702000).
Biological Activity
s-ruxolitinib is the chirality of incb018424, is a potent and selective small-molecule janus kinase 1 (jak1) and jak2 inhibitor. it was initially developed to target the constitutive activation of the jak-stat pathway. janus kinases (jaks) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. ruxolitinib maintains its anti-jak activity by competitive inhibition of the atp-binding catalytic site of the kinase domain. ruxolitinib is well absorbed at >95%. exposure of jak2v617f-positive ba/f3 cells to ruxolitinib iss shown to result in reduced cellular proliferation.ruben a. mesa, uma yasothan, peter kirkpatrick. ruxolitinib. nature reviews drug discovery. 2012; 11: 103-104john mascarenhas, ronald hoffman. ruxolitinib: the first fda approved therapy for the treatment of myelofibrosis. clinical cancer research. 2012; 18(11): 3008 - 3014
Properties of S-Ruxolitinib (INCB018424)
Melting point: | 138-143oC |
Density | 1.40±0.1 g/cm3(Predicted) |
storage temp. | -20°C Freezer |
solubility | DMSO (Slightly), Methanol (Slightly) |
form | Solid |
pka | 11.63±0.50(Predicted) |
color | White |
Safety information for S-Ruxolitinib (INCB018424)
Computed Descriptors for S-Ruxolitinib (INCB018424)
New Products
6-Bromo 2-Iodo Indole Pyridine 2,4,6-Tricarboxaldehyde Ivermectin EP Impurity B Rimegepant Impurity 3 Fosfomycin EP impurity D Tubulysin E Tubulysin I Tubulysin A 2,2-diethoxyethanethioamide 2-[2-[3(S)-3[2-(7-chloro-2-quinolinyl) ethenyl] phenyl-3- hydroxyl propyl] phenyl]-2-propanol Imeglimin Hydrochloride IH Fuel shell Calcium Sodium Phosphosilicate IH 2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol ethanedioate 2-(1-(Mercaptomethyl) cyclopropyl) acetonitrile 4-Bromo-N,N-bis(4-iodophenyl)aniline 2-(4-Bromopyridin-2-yl)acetonitrile 4-(Azidomethyl)-3-chloropyridine 3,3,6,6-Tetramethylcyclohexane-1,2-dione Methyl 4-amino-3-(4-phenylpiperazin-1-yl)benzoate 3,6-Bis(4-iodophenyl)-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-dione 1-(4-Bromophenyl)cyclobutanol 3-bromo-5-fluorobenzaldehyde 3,3-dimethyl-2-oxo-, methyl esterRelated products of tetrahydrofuran
You may like
-
3,6-Bis(4-iodophenyl)-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-dioneView Details
952145-70-9 -
1262243-12-8View Details
1262243-12-8 -
Rimegepant Impurity 3View Details
-
Sidchem 730View Details
-
Sidchem BT 20View Details
-
1572177-89-9View Details
1572177-89-9 -
6390-09-6View Details
6390-09-6 -
6-Bromo indoleView Details